MEDA introduces EDLUAR™, the first and only sublingual tablet that contains the most prescribed sleep medication, zolpidem tartrate
- [September, 2009]
MEDA receives FDA approval of new ASTEPRO® (azelastine HCl) nasal spray 0.15%, the first and only once-daily nasal antihistamine
- [September, 2009]
FDA approval for Onsolis anticipated during summer 2009
- [June, 2009]
Positive study supporting a potential once-daily nasal antihistamine
- [May, 2009]
Edluar receives FDA approval
- [March, 2009]
FDA has accepted for filing the first potential once-a-day nasal antihistamine
- [October, 2008]
The FDA approves Astepro
- [October, 2008]
Anticipated approval of OnsolisTM during first half 2009
following receipt of Complete Response letter from FDA
- [August, 2008]
Meda has settled the U.S. Astelin patent litigation with Cobalt
- [August, 2008]
Meda acquires product portfolio from Roche
- [August, 2008]
Registration application for azelastine Extra Strength submitted to the FDA
- [August, 2008]
The FDA has accepted for filing the registration application for Sublinox
- [July, 2008]
FDA approves azelastine eye drops unit dose
- [July, 2008]
FDA requests more information on new azelastine formulation
- [June, 2008]
Sublinox registration application submitted to the FDA
- [May, 2008]
Meda has settled the U.S. Astelin® patent litigation with Apotex
- [April, 2008]
Further inquiries should be directed to info@medapharma.us
| 
